Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ACONBullishCorporate Developmentsnews

High materiality8/10

Aclarion Expands CLARITY with NYU Langone to Bolster Nociscan Evidence

Sep 29, 2026, 7:12 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Addition of a top academic site can accelerate enrollment and data generation, supporting a more convincing value proposition for Nociscan and potentially lifting ACON/ACONW valuation. Risks include clinical outcome uncertainty and competition; no immediate revenue.

AI summary

What happened, with direct paths to the underlying reporting

ACRON? Aclarion announces NYU Langone Health as a new CLARITY trial site for Nociscan, expanding enrollment in the 300-patient randomized study. The addition of a top-tier spine program bolsters credibility and could accelerate data accrual, potentially validating Nociscan's clinical and economic value and guiding broader adoption.

NYU Langone Health adds CLARITY trial site. Expands enrollment for Nociscan.
CLARITY is a 300-patient randomized trial. Evaluates Nociscan's surgical value.
Nociscan uses MRS and AI to locate painful discs. Reports 97% surgical success when all positive discs are treated.
ACON/ACONW stock may react to CLARITY milestones.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.